A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
Clinical trial NCT02989402 · COMPLETED
Trial details
- NCT number
- NCT02989402
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-31
- Primary completion
- 2022-12-07
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.